在接受rAHF治疗的72名患者中(全部男性),有61名患者包含在符合方案分析集中(图2)。患者基线特征如表1所示。 👉疗效: rAHF按需治疗组平均总ABR为58.3(95%CI,52.5-64.7;中位[范围],53.9 [16.7–121.7])相对于预防治疗ABR为2.5(95%CI,1.5–3.7;中位数[范围],0.0 [0.0–22.1]),平均ABR降低95.9%(图3)。
网络重组抗血友病因子 网络释义 1. 重组抗血友病因子 ... FDA近日批准ADVATE无血浆/血清方法制备的重组抗血友病因子(rAHF-PFM)用于预防和控制甲型血友病患者的出血症状或用 … www.100md.com|基于 1 个网页
rAHF-PFM, the first third-generation recombinant Factor VIII concentrate, has been under clinical evaluation since November, 2000. No materials of human or animal origin are used in the production and final formulation of rAHF-PFM. To achieve this, the cell culture used to produce Recombinate, ...
Factor VIII--Baxter: rAHF-PFM, recombinant anti-haemophilic factor--protein-free method, recombinant factor VIII--protein-free. 来自 掌桥科研 喜欢 0 阅读量: 25 作者: Limited A.I 摘要: Baxter Healthcare is developing a next-generation recombinant factorVIII for the treatment of haemophiliaA ...
rAHF-PFM, the first third-generation recombinant Factor VIII concentrate, has been under clinical evaluation since November, 2000. No materials of human or animal origin are used in the production and final formulation of rAHF-PFM. To achieve this, the cell culture used to produce Recombinate, ...
Stability of lyophilized and reconstituted plasma/albumin-free recombinant human factor VIII (ADVATE rAHF-PFM) Haemophilia. 2005; 11 :492–496.Parti R, Schoppmann A, Lee H, Yang L. Stability of lyophilized and re- constituted plasma/albumin-free recombinant human factor VIII (ADVATE rAHF-PFM)....
Impact of rAHF-PFM prophylactic treatment on annual bleeding rate and health-related quality of life of adults with severe hemophilia AQuon, D VShapiro, A DSantagostino, EValentino, L AEpstein, J DGuzmanBecerra, NSchroth, P HWong, W Y...
Clinical eval- uation of a new generation recombinant FVIII, plasma/albumin- free method (rAHF-PFM). Blood 2002;100:493a[abstract].Tarantino MD, Navale LM, Bray GL, Ewenstain BM. Clinical evaluation of a new generation recombinant FVIII, plasma/ albumin-free method (rAHF-PFM). ...
PBR2 ECONOMIC IMPACT OF ANTIHEMOPHILIC FACTOR (RECOMBINANT), PLASMA/ALBUMIN-FREE METHOD (RAHF-PFM) IN PATIENTS WITH HEMOPHILIA Adoi:10.1016/S1098-3015(10)65934-7KC ChungValue in Health
Simeonov, Superior pharmacokinetics with BAY 81-8973 versus antihemophilic factor (recombi- nant) plasma/albumin-free method (rAHF-PFM): a single-dose, randomized, crossover study in patients with severe hemophilia A, Haemophilia 22 (2016) 104, http://dx.doi.org/10.1111/hae.1_12882....